Capital A Wealth Management LLC Purchases Shares of 1,591 Zoetis Inc. (NYSE:ZTS)

Capital A Wealth Management LLC bought a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,591 shares of the company's stock, valued at approximately $259,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ZTS. Cypress Asset Management Inc. TX acquired a new position in shares of Zoetis in the fourth quarter valued at about $4,593,000. American Trust grew its position in shares of Zoetis by 9.3% during the 4th quarter. American Trust now owns 16,877 shares of the company's stock worth $2,750,000 after purchasing an additional 1,430 shares in the last quarter. Perennial Advisors LLC acquired a new position in shares of Zoetis during the 4th quarter worth approximately $3,751,000. Value Partners Investments Inc. increased its holdings in shares of Zoetis by 6.4% during the fourth quarter. Value Partners Investments Inc. now owns 12,414 shares of the company's stock worth $2,021,000 after purchasing an additional 749 shares during the period. Finally, Wormser Freres Gestion raised its position in shares of Zoetis by 0.8% in the fourth quarter. Wormser Freres Gestion now owns 45,207 shares of the company's stock valued at $7,419,000 after buying an additional 380 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Insider Transactions at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the sale, the director now directly owns 11,245 shares in the company, valued at $1,868,244.30. This trade represents a 9.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the transaction, the executive vice president now owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.18% of the company's stock.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus reduced their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Barclays increased their target price on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a report on Friday, February 14th. UBS Group decreased their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Morgan Stanley cut their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. Finally, Piper Sandler increased their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Zoetis presently has a consensus rating of "Buy" and a consensus target price of $212.75.

Zoetis Price Performance

Zoetis stock traded up $1.57 during midday trading on Friday, reaching $168.71. The company's stock had a trading volume of 5,467,766 shares, compared to its average volume of 2,534,765. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a market cap of $75.11 billion, a PE ratio of 30.84, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The business has a 50-day moving average price of $156.65 and a 200-day moving average price of $164.63.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period last year, the company posted $1.38 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. The ex-dividend date is Friday, July 18th. Zoetis's payout ratio is 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.